Lataa...
A rare epidermal growth factor receptor H773L/V774M compound mutation in advanced non‐small‐cell lung cancer with poor response to epidermal growth factor receptor tyrosine kinase inhibitor
Uncommon mutations account for 10–15% of epidermal growth factor receptor (EGFR) mutations in patients with non‐small‐cell lung cancer. Afatinib is currently the most efficient EGFR‐tyrosine kinase inhibitor (TKI) against uncommon EGFR mutations. Here we report a 56‐year‐old woman presenting with pe...
Tallennettuna:
| Julkaisussa: | Respirol Case Rep |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Ltd
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6456914/ https://ncbi.nlm.nih.gov/pubmed/31007929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.425 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|